The Influence of Different Thyroid Autoantibodies on Thyroid Function and Pregnancy Outcome After Assisted Reproductive Technology

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT04019509

Acronym

TgAB

Enrollment

900

Registered

2019-07-15

Start date

2019-01-01

Completion date

2022-09-01

Last updated

2019-07-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Fertility Disorders, Thyroid Dysfunction

Brief summary

The influence of thyroid autoantibodies on thyroid function in pregnancy after fertility treatment is not well known. The objectives of the present study are: 1. To monitor the course of thyroid function during pregnancy and to compare between women with and without thyroid autoantibodies. 2. Compare pregnancy outcome between women with and without thyroid antibodies

Detailed description

Thyroid autoantibodies and / or abnormal thyroid function are associated with fertility problems. A possible explanation for this is, an influence of thyroid autoantibodies on the functioning of the thyroid gland. It is therefore recommended to check thyroid gland function and for the presence of autoantibodies before pregnancy. In general, 2 types of thyroid autoantibodies are known: anti-thyreoperoxidase autoantibodies and anti-thyroglobulin autoantibodies. In case of abnormal thyroid function, treatment is sometimes necessary in regards to fertility. The risk of abnormal thyroid function is increased in women with thyroid autoantibodies during pregnancy. Therefore, thyroid function is regularly monitored during pregnancy in women with thyroid antibodies. The influence of thyroid autoantibodies on thyroid function in pregnancy after fertility treatment is not well known. The objectives of the present study are: 1. To monitor the course of thyroid function during pregnancy and to compare between women with and without thyroid autoantibodies. 2. Compare pregnancy outcome between women with and without thyroid antibodies

Interventions

DIAGNOSTIC_TESTblood test

blood test for thyroid antibodies and thyroid function (TSH, FT4)

OTHERfollow up treatment outcome

questionnaire for treatment outcome: pregnancy, no pregnancy, miscarriage, delivery

Study design

Allocation

NON_RANDOMIZED

Intervention model

FACTORIAL

Primary purpose

DIAGNOSTIC

Masking

NONE

Eligibility

Sex/Gender

FEMALE

Age

18 Years to 36 Years

Healthy volunteers

Yes

Inclusion criteria

* first cycle of assisted reproductive technology with follow up of thyroid function at the Universitair Ziekenhuis Brussel * age \>= 18 and \<= 36 years * body mass index between 18 and 35

Exclusion criteria

* Patients with clinical thyroid dysfunction * Patients being treated with levothyroxine or antithyroid drugs * Patients being treated with glucocorticosteroids * Patients undergoing in vitro maturation or preimplantation genetic testing. * Poor responders during IVF/ICSI stimulation, using the Bologna criteria

Design outcomes

Primary

Measure	Time frame	Description
thyroid fonction	12 months	TSH, FT4 evolution during pregnancy
cumulative delivery rate	12 months	live birth delivery after IVF stimulation

Secondary

Measure	Time frame	Description
cumulative pregnancy rate	12 months	pregnancy rate after IVF stimulation
miscarriage rate	12 months	miscarriage rate after IVF stimulation

Countries

Belgium

Contacts

Primary Contactvalerie uvin, md

valerieuvin@hotmail.com486073292

Backup Contactdavid unuane, md phd

david.unuane@uzbrussel.be024774671

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026